Bristol-Myers Squibb (NYSE:BMY) said today that it landed an exclusive licensing agreement for PsiOxus Therapeutics‘ ‘armed’ oncolytic virus, NG-348, for the treatment of solid tumors.
According to the agreement, Bristol-Myers will pay PsiOxus $50 million upfront and will assume responsibility for global clinical development and commercialization. PsiOxus will be eligible for $886 million in development, regulatory and sales-based milestones. New York-based Bristol-Myers will be responsible for funding the preclinical development of NG-348.
Get the full story at our sister site, Drug Delivery Business News.
The post Bristol-Myers, PsiOxus land licensing agreement appeared first on MassDevice.